Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing device-based treatments for Substance Use Disorders (SUDs) through a cooperative agreement. The initiative seeks to expedite the development and FDA approval of innovative neuromodulatory devices, with a focus on both pre-clinical and clinical phases, and encourages the exploration of existing devices approved for other conditions. This funding opportunity follows a two-phase approach (UG3/UH3), where the UG3 phase supports projects for up to two years, and the UH3 phase provides additional funding for successful projects for up to three more years. Applications open on November 18, 2023, with the first funding start date set for December 18, 2023. Eligible applicants include a wide range of institutions, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-253.html.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.